NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Forecast & News

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, October, 31st. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.10 by $0.30. The biotechnology company had revenue of $131.17 million for the quarter, compared to the consensus estimate of $97.10 million. Ironwood Pharmaceuticals had a negative net margin of 9.67% and a negative return on equity of 15.83%. The firm's revenue was up 99.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Ironwood Pharmaceuticals.

10 analysts have issued 1 year price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $14.67 in the next year. This suggests a possible upside of 17.8% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Media stories about IRWD stock have been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (3.72%), Peregrine Capital Management LLC (0.81%), Millennium Management LLC (0.66%), Colony Group LLC (0.33%), Squarepoint Ops LLC (0.25%) and Chicago Equity Partners LLC (0.25%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, SG Americas Securities LLC, First Trust Advisors LP, Broderick Brian C and Chicago Equity Partners LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Colony Group LLC, Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Peregrine Capital Management LLC, First Quadrant L P CA and Redwood Investment Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $12.45.

Ironwood Pharmaceuticals has a market capitalization of $1.95 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]